BioCardia to Present at 2015 Stem Cell Meeting on the Mesa

October 06, 2015

SAN CARLOS, CA (GlobeNewswire) – BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases announced today that Peter Altman, Chief Executive Officer will present at the annual Partnering Forum of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.

Event:

2015 Stem Cell Meeting on the Mesa – Partnering Forum

Date: 

October 07, 2015

Time: 

1:30 p.m. PDT

Location: 

Estancia La Jolla Hotel & Spa
9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast will be available here. Please visit this site for full information.

This conference brings together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.


About BioCardia, Inc.
BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ cell therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Contact:
Miranda Peto Benvenuti MPeto@BioCardia.com

News

28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More
24 May

Fox 47

UW Health trial involves injecting stem cells into patients with heart failure
Read More

press releases

01 Jul
2020 BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia
29 Jun
2020 BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
17 Jun
2020 BioCardia Announces Pricing of $10.0 Million Public Offering
15 May
2020 BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
05 May
2020 BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
30 Apr
2020 BioCardia Announces FDA-Recommended Modifications to Primary Endpoint for CardiAMP Cell Therapy Heart Failure Trial to Support Marketing Approval
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS